论文部分内容阅读
目的:探讨顺铂+多西紫杉醇、顺铂+吉西他滨、顺铂+长春瑞滨等三组联合化疗方案用于治疗晚期非小细胞肺癌的临床疗效。方法:选择2008年5月~2012年9月我院化疗科收治的晚期非小细胞肺癌患者84例,随机分为DP组、GP组、NP组各28例,分别给予顺铂+多西紫杉醇、顺铂+吉西他滨、顺铂+长春瑞滨治疗,比较3组患者有效率、生存率及不良反应情况。结果:3组患者总有效率为39.3%,总肿瘤控制率为73.8%,各组间有效率和肿瘤控制率差异无统计学意义(P>0.05)。DP组、GP组、NP组中位生存时间分别为11.5、12.2、11.8个月,1年生存率分别为36.9%、43.2%、35.1%,各组间生存时间和生存率比较均无显著性差异(P>0.05)。结论:3种含顺铂的3组联合化疗方案均有较好的疗效,临床上应根据药物毒副作用和患者耐受情况选择合适方案,
Objective: To investigate the clinical efficacy of three combined chemotherapy regimens of cisplatin + docetaxel, cisplatin + gemcitabine, cisplatin + vinorelbine in the treatment of advanced non-small cell lung cancer. Methods: From May 2008 to September 2012, 84 patients with advanced non-small cell lung cancer admitted to our department of chemotherapy in our hospital were randomly divided into DP group, GP group and NP group, 28 cases were given cisplatin + docetaxel , Cisplatin + gemcitabine, cisplatin + vinorelbine treatment, the efficacy of three groups were compared, the survival rate and adverse reactions. Results: The total effective rate of the three groups was 39.3%, the total tumor control rate was 73.8%. There was no significant difference between the three groups in the effective rate and the tumor control rate (P> 0.05). The median survival time of DP group, GP group and NP group were 11.5, 12.2 and 11.8 months, respectively, and the 1-year survival rates were 36.9%, 43.2% and 35.1% respectively. There was no significant difference in survival time and survival rate between the groups Difference (P> 0.05). CONCLUSION: All three kinds of combination chemotherapy regimens containing cisplatin have a good curative effect. According to the drug side effects and patient tolerance, we should choose the appropriate program in clinical practice,